[CAS NO. 341001-38-5] Nucleozin
PRODUCTS SPECIFICATIONS [341001-38-5]
DESCRIPTION [341001-38-5]
Overview
| MDL | MFCD01426660 |
|---|---|
| Molecular Weight | 426.85 |
| Molecular Formula | C21H19ClN4O4 |
| SMILES | CC1=C(C(C2=CC=CC=C2)=NO1)C(N3CCN(C4=C(C=C(C=C4)[N+]([O-])=O)Cl)CC3)=O |
2 Publications Citing Use of MCE
Summary
In Vitro
Nucleozin inhibits infection of MDCK cells by the viruses influenza A/WSN/33, H3N2 and Vietnam/1194/04 (H5N1) with an EC 50 of 0.069 μM, 0.16 μM and 0.33 μM in plaque reduction assay (PRA) , respectively, severely suppresses viral growth at 0.1 μM and totally inhibites virus production at 1 μM in multicycle growth assays [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Nucleozin protectes mice challenged with lethal doses of avian influenza A H5N1 [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 20 mg/mL ( 46.85 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3427 mL | 11.7137 mL | 23.4274 mL |
| 5 mM | 0.4685 mL | 2.3427 mL | 4.6855 mL |
| 10 mM | 0.2343 mL | 1.1714 mL | 2.3427 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2 mg/mL (4.69 mM); Suspended solution; Need ultrasonic